New hope for kids with rare Muscle-Weakening disease: drug trial launches

NCT ID NCT06987539

Recruiting now Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times

Summary

This study tests a drug called inebilizumab in 15 children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The main goals are to see how the drug moves through the body, how safe it is, and whether it helps control symptoms. The drug is given through an IV and works by targeting certain immune cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inebilizumab
What this could lead to: If successful, this could provide a new treatment option for children with generalized myasthenia gravis, helping to control muscle weakness and improve daily life.
What could go wrong: This is a small, early-phase study (15 children) focused on safety and dosing, not proof of effectiveness. The drug may not work as well in children or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GENERALIZED MYASTHENIA GRAVIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GENERALIZED MYASTHENIA GRAVIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Austin Neuromuscular Center
RECRUITING

Austin, Texas, 78759, United States
Hopital Armand Trousseau
RECRUITING

Paris, 75012, France
Hospital Universitari i Politecnic La Fe
RECRUITING

Valencia, 46026, Spain
John Radcliffe Hospital
NOT_YET_RECRUITING

Headington, Oxford, 9DU, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.